Cargando…

EZH2 expression is associated with inferior overall survival in mantle cell lymphoma

Enhancer of zeste homolog 2 (EZH2) is a catalytic component of the polycomb repressive complex 2 (PRC2) which reduces gene expression via trimethylation of a lysine residue of histone 3 (H3K27me3). Expression of EZH2 has not been assessed systematically in mantle cell lymphoma (MCL). Expression of E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martinez-Baquero, Diana, Sakhdari, Ali, Mo, Huan, Kim, Do Hwan, Kanagal-Shamanna, Rashmi, Li, Shaoying, Young, Ken H., O’Malley, Dennis P., Dogan, Ahmet, Jain, Preetesh, Wang, Michael L., McDonnell, Timothy J., Miranda, Roberto N., Vega, Francisco, Medeiros, L. Jeffrey, Ok, Chi Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563799/ https://www.ncbi.nlm.nih.gov/pubmed/34376807 http://dx.doi.org/10.1038/s41379-021-00885-9

Ejemplares similares

Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features
por: Khanlari, Mahsa, et al.
Publicado: (2023)

Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma
por: Jain, Preetesh, et al.
Publicado: (2023)

RAS and TP53 can predict survival in adults with T‐cell lymphoblastic leukemia treated with hyper‐CVAD
por: Sakhdari, Ali, et al.
Publicado: (2019)

MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma
por: Wang, Lifu, et al.
Publicado: (2020)

Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
por: Hill, Holly A., et al.
Publicado: (2023)

Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies
por: El Achi, Hanadi, et al.
Publicado: (2021)

Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report
por: Burgos, Sebastian, et al.
Publicado: (2019)

Advances in the assessment of minimal residual disease in mantle cell lymphoma
por: Jung, Dayoung, et al.
Publicado: (2020)

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma
por: Zhang, Shaojun, et al.
Publicado: (2021)

Nucleophosmin 1 Mutations in Acute Myeloid Leukemia
por: Zarka, Jabra, et al.
Publicado: (2020)

Smudge cells in CD200(+), TP53 mutated leukemic mantle cell lymphoma
por: Jain, Preetesh, et al.
Publicado: (2022)

Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab
por: Jain, Punit, et al.
Publicado: (2016)

Consolidative opacity in a patient with acute leukemia
por: Banala, Chaitra, et al.
Publicado: (2022)

LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2
por: Wang, Xin, et al.
Publicado: (2016)

BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner
por: Munoz, Javier L., et al.
Publicado: (2022)

Over-Expression of CYP2E1 mRNA and Protein: Implications of Xenobiotic Induced Damage in Patients with De Novo Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFβ-MYH11
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2012)

Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms
por: Zuo, Zhuang, et al.
Publicado: (2022)

Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing
por: Quesada, Andrés E., et al.
Publicado: (2018)

Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
por: Beitinjaneh, Amer, et al.
Publicado: (2022)

Arthroscopic Management of Posterior Instability due to “Floating” Posterior Inferior Glenohumeral Ligament Lesions
por: O'Malley, Lawrence, et al.
Publicado: (2017)

Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report
por: Huang, Lanshan, et al.
Publicado: (2016)

The role of EZH2 in overall survival of colorectal cancer: a meta-analysis
por: Vilorio-Marqués, Laura, et al.
Publicado: (2017)

Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma
por: Bijou, Imani, et al.
Publicado: (2023)

CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases
por: Xu, Jie, et al.
Publicado: (2017)

A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma
por: PAOLICCHI, ELISA, et al.
Publicado: (2013)

CDKN1C‐mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib
por: Kagiyama, Yuki, et al.
Publicado: (2021)

An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma
por: Boddu, Prajwal, et al.
Publicado: (2017)

Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2017)

Comparison of Colour Duplex Ultrasound with Computed Tomography to Measure the Maximum Abdominal Aortic Aneurysmal Diameter
por: Gray, C., et al.
Publicado: (2014)

Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma
por: Sircar, Anuvrat, et al.
Publicado: (2023)

The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis
por: Fischer, Luca, et al.
Publicado: (2023)

A smartphone intervention for adolescent obesity: study protocol for a randomised controlled non-inferiority trial
por: O’Malley, Grace, et al.
Publicado: (2014)

High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis
por: Li, Philippa, et al.
Publicado: (2021)

Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era
por: Montes-Moreno, Santiago, et al.
Publicado: (2018)

Incidental identification of inv(16)(p13.1q22)/CBFB–MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy
por: Quesada, Andrés E., et al.
Publicado: (2021)

Mantle Cell Lymphoma Mimicking Rectal Carcinoma
por: Kelkitli, Engin, et al.
Publicado: (2014)

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
por: Ok, Chi Young, et al.
Publicado: (2019)

Synchronous Adenocarcinoma and Mantle Cell Lymphoma of the Stomach
por: Kim, Yong Il, et al.
Publicado: (2007)

Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations
por: Che, Yuxuan, et al.
Publicado: (2023)

High EZH2 Protein Expression Is Associated with Poor Overall Survival in Patients with Luminal A Breast Cancer
por: Jang, Si-Hyong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_e402p4j55rvalums6qa64ppknu